We aimed to investigate the association between drooling and possible etiological factors in Parkinson's disease (PD) and to determine its effect on the quality of life. Demographic data of the 63 patients with idiopathic PD were recorded. Radboud Oral Motor Inventory for Parkinson's disease (ROMP) test was administered to all patients to evaluate speech, swallowing functions, and saliva control. The freezing of gait questionnaire (FOGQ) was used to evaluate gait and freezing of gait. Dynamic Parkinson gait scale (DYPAGS) was administered for the objective quantification of PD gait features. Disease severity was assessed by UPDRS and modified Hoehn & Yahr Scale. PD specific health-related quality was evaluated by PDQ-39 questionnaire. Drooling was only significantly correlated to UPDRS score; a stronger association was found between drooling and UPDRS 3 motor score; and a more significant association was determined between drooling and the bradykinesia questions of the motor part of UPDRS 3. Interestingly, no significant association was found between sialorrhea score and PDQ-39 score. Based on the results of this study, we concluded that oropharyngeal bradykinesia may be responsible for drooling in PD. In contrast to a general expectation, we did not find any adverse impact of drooling on the quality of life.
Aim In this study, we aimed to show non‐motor symptoms (NMS), in addition to motor symptoms, in the foreground of idiopathic Parkinson's disease (IPD). We also examined the prevalence of dopamine dysregulation syndrome, which can be evaluated based on NMS, its risk factors, and its effects on quality of life (QOL) by using various scales and questionnaires. Methods In total, 75 patients with IPD (46 men, 29 women) who attend the outpatient neurology clinic of our hospital were included in the study. The motor symptoms and NMS of IPD were examined. The severity of parkinsonism was evaluated with the Unified Parkinson's Disease Rating Scale and the Hoehn and Yahr scale. Cognitive tests, the NMS questionnaire, the Parkinson's Disease Sleep Scale, and the Dopamine Dysregulation Syndrome‐Patient and Caregiver Inventory were used to identify NMS. The 39‐item Parkinson's Disease Questionnaire evaluated QOL. Results We observed a significant increase in scores on the tests assessing NMS, specifically the Parkinson's Disease Questionnaire, NMS questionnaire, Parkinson's Disease Sleep Scale, and Geriatric Depression Scale (P < 0.05). These increases correlated with an increase in the Unified Parkinson's Disease Rating Scale score and a stage increase on the Hoehn and Yahr scale. Based on the scores, motor severity most affected QOL. Conclusion Ignoring NMS while focusing primary on motor symptoms in IPD can cause serious insufficiencies in treatment plans. Assessing NMS and dopamine dysregulation syndrome with structured scales that employ an integrated approach can improve QOL in IPD.
Objective SCUBE1 [signal peptide-CUB (complement C1r/C1 s)-EGF (epidermal growth factor)-like domain-containing protein 1] is a novel biochemical marker. SCUBE1 is thought to play roles both in platelet activation and inflammation, which are important stages for the development of acute ischemic stroke (AIS).The purpose of our study was to determine the diagnostic and prognostic values and temporal change of plasma SCUBE1 levels in AIS patients. Materials and methods Thirty-five patients diagnosed with AIS at the Cumhuriyet University Faculty of Medicine Neurology Department, between June and December 2017, and a control group of 35 healthy volunteers were included. Results Median first day SCUBE1 value in the patient group was 97.51 ng/mL, and the median 7th day SCUBE1 value was 32.72 ng/mL. Median control group SCUBE1 value was 27.51 ng/mL. The first day SCUBE1 levels were significantly higher than the 7th day and the control group SCUBE1 levels (p=0.001, p<0.001, respectively). The ROC analysis showed that SCUBE1 levels above 68.8 ng/mL can be used as an indicator with high sensitivity and specificity for AIS diagnosis. Multivariate analysis revealed that the first day SCUBE1 had significant independent effects on development of AIS. In correlation analysis, plasma SCUBE1 levels showed a significantly positive correlation with lesion volume, NIHSS and MRS values (p<0.01). Conclusion First day plasma SCUBE1 values in AIS patients rised at significant levels compared to the control group. SCUBE1 could use both in the early diagnosis and prediction of prognosis and lesion volume of AIS patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.